AGIO:NASDAQ
Agios Pharmaceuticals Inc
$29.42
arrow_downward
-1.57%(-0.47) 1D
Nov 18, 12:40:58 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
$29.57
High
$30.48
Low
$29.22
Mkt. cap
1.76B
Avg. vol.
1.21M
Volume
94.48K
52-wk high
$44.07
52-wk low
$22.24
EPS
-$6.32
Beta
0.66
Shares outstanding
59.81M
No. of employees
540
Open
$29.57
High
$30.48
Low
$29.22
Mkt. cap
1.76B
Avg. vol.
1.21M
Volume
94.48K
52-wk high
$44.07
52-wk low
$22.24
EPS
-$6.32
Beta
0.66
Shares outstanding
59.81M
No. of employees
540
News stories
From web sources and news partners
Invezz
·
45 minutes ago
UBS predicts S&P 500 moving up 12% in 2027 but flags major risks around AI
24/7 Wall St.
·
34 minutes ago
S&P 500 Slides 0.6% at Midday as the Dow Drops Over 1%
TradingView
·
2 hours ago
S&P 500, Nasdaq find footing as Nvidia treads water
JournalArta
·
40 minutes ago
S&P 500 Futures Rise After Nvidia Raises Sales Forecast
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc